Bayer's Split Ambitions Shelved as Broker Targets Diverge Over Sunharbo
Published on 11/11/2026 at 08:21 | Editorial boerse-global.de
Bayer chief executive Bill Anderson used a November 3 appearance to pour cold water on the idea of breaking up the conglomerate, telling audiences that a demerger is not currently on the agenda. Media reports suggest the group would rather channel its energies into innovation and paying down debt — a strategic anchor that gives investors a clearer frame for judging the flurry of news now hitting the stock.
That frame matters, because the shares are no longer cheap in the eyes of everyone watching. Bayer has climbed 55% since the start of the year, a run that raises the bar for what the company must deliver operationally to keep the momentum alive. The stock added 0.5% on the day in question to close at €57.22 — comfortably above the €48.50 target that Jefferies still carries.
Two Houses, One Newsflow, Opposite Conclusions
The trigger for the latest bout of attention was the US approval of Asundexian, which the FDA cleared under the brand name Sunharbo for reducing the risk of a repeat stroke when used alongside an antiplatelet therapy. Bayer bills the compound as the world's first approved factor XIa inhibitor. Reuters linked the intraday share-price strength directly to that regulatory green light.
Jefferies, however, was unmoved. Analyst Michael Leuchten called the approval expected and kept his hold rating intact, even while conceding that it meaningfully lowers the risk attached to Bayer's pharmaceutical pipeline. Deutsche Bank Research took the other side of the trade: it lifted its price target from €60 to €65 and reiterated its buy call, citing higher earnings estimates following the third quarter. The two houses therefore remain at odds on both rating and target — a split that leaves shareholders to weigh how much operational progress is already baked into the price.
Should investors sell immediately? Or is it worth buying Bayer?
The Earnings Test
What separates the bulls from the fence-sitters is ultimately the bottom line. The metric to watch is EBITDA before special items, since that is where an improved pharma outlook either shows up at group level or fails to.
Bayer's third-quarter 2026 release, published roughly a week before the approval news, offered some encouragement. Revenue came in at €10.053 billion, with EBITDA before special items of €1.615 billion. The company also raised its full-year guidance, attributing the upgrade — according to Reuters — to a better-than-expected performance in the pharmaceuticals division. That gives the optimistic case a tangible operational footing, though a fuller re-rating would require the improvement to persist and the drug pipeline to keep carrying group earnings.
In the bull scenario, the two forces reinforce each other: a de-risked pipeline plus stronger operating momentum. Should Bayer convert its regulatory wins into commercial success, the pharma unit would keep justifying the raised outlook and could underpin further earnings gains.
What Could Go Wrong
The bear argument rests on how far the stock has already travelled. After a 55% year-to-date advance, further upside depends heavily on Bayer confirming elevated expectations with hard numbers. Jefferies' stance is a serious counterweight to Deutsche Bank's more bullish read — Leuchten acknowledges the substantial drop in pipeline risk yet still recommends holding, a signal for caution among investors who assess the commercial contribution of those advances in similar fashion.
A slower-than-hoped earnings trajectory would widen the gap between business progress and market valuation, turning that divergence into a drag. The pressure would intensify if the pharma division lent less support to the higher profit forecasts than optimists assume.
Bayer at a turning point? This analysis reveals what investors need to know now.
Roundup and the Road Ahead
On the litigation front, Bayer subsidiary Monsanto won its first case in Missouri on October 30 since the US Supreme Court ruling, with the company stating that the plaintiffs had produced no evidence for alternative grounds of claim. The verdict offers a measure of relief in the long-running glyphosate complex.
Looking forward, the next real test will be further operating results and commentary on how the approvals are being commercialised. That is where it becomes clear whether a reduced development risk translates into a durably stronger earnings base — or whether the market has simply run ahead of the business.
Ad
Bayer Stock: New Analysis - 11 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
